Evidence map›Paper›PMID 25795498›Full record

ReviewSeminars in nephrology2015

Emerging therapeutic targets of sepsis-associated acute kidney injury.

Sundararaman Swaminathan, Mitchell H Rosner, Mark D Okusa

Abstract readReview
In one paragraph

Review in Seminars in nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Trial
  2. Urinary UDP-sugars provide actionable prediction of acute kidney injury in cardiac surgery patients.American journal of physiology. Heart and circulatory physiology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. The renal level of a novel cytokine IL-35 is related to sepsis-associated acute kidney injury in mice.International journal of clinical and experimental pathology · 2017
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sundararaman SwaminathanDivision of Nephrology, Center for Immunity, Inflammation and Regenerative Medicine, University of Virginia Health System, Charlottesville, VA.
Mitchell H RosnerDivision of Nephrology, Center for Immunity, Inflammation and Regenerative Medicine, University of Virginia Health System, Charlottesville, VA.
Mark D OkusaDivision of Nephrology, Center for Immunity, Inflammation and Regenerative Medicine, University of Virginia Health System, Charlottesville, VA. Electronic address: mdo7y@virginia.edu.

Funding

Sphingolipids in Acute Kidney Injury and Disease ProgressionR01DK085259 · NIDDK · UNIVERSITY OF VIRGINIA · PI OKUSA, MARK DOUGLAS · 2010 to 2023
$5.0M
Leukocyte Trafficking in Acute Renal FailureR01DK062324 · NIDDK · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI OKUSA, MARK DOUGLAS · 2003 to 2016
$4.4M
Nanotherapeutics for acute kidney injuryR21DK093841 · NIDDK · UNIVERSITY OF VIRGINIA · PI KLIBANOV, ALEXANDER L, OKUSA, MARK DOUGLAS · 2012 to 2013
$425k
NIDDK NIH HHS DK062324NIDDK NIH HHS DK085259NIDDK NIH HHS DK093841NIDDK NIH HHS R01 DK062324NIDDK NIH HHS R01 DK085259NIDDK NIH HHS R21 DK093841
6 · The paper itself

Abstract

Sepsis-associated acute kidney injury (SA-AKI) is linked to high morbidity and mortality. To date, singular approaches to target specific pathways known to contribute to the pathogenesis of SA-AKI have failed. Because of the complexity of the pathogenesis of SA-AKI, a reassessment necessitates integrative approaches to therapeutics of SA-AKI that include general supportive therapies such as the use of vasopressors, fluids, antimicrobials, and target-specific and time-dependent therapeutics. There has been recent progress in our understanding of the pathogenesis and treatment of SA-AKI including the temporal nature of proinflammatory and anti-inflammatory processes. In this review, we discuss the clinical and experimental basis of emerging therapeutic approaches that focus on targeting early proinflammatory and late anti-inflammatory processes, as well as therapeutics that may enhance cellular survival and recovery. Finally, we include ongoing clinical trials in sepsis.

Indexed as

Acute Kidney InjuryAlkaline PhosphataseAnti-Bacterial AgentsCell- and Tissue-Based TherapyEndocannabinoidsFluid TherapyGranulocyte-Macrophage Colony-Stimulating FactorHumansNeuroimmunomodulationPPAR alphaSepsisShock, SepticThrombomodulinVasoconstrictor AgentsAlkaline PhosphataseAnti-Bacterial AgentsEndocannabinoidsGranulocyte-Macrophage Colony-Stimulating FactorPPAR alphaThrombomodulinVasoconstrictor AgentscytokinesInflammationseptic shocktherapeutics

Identifiers

PMID25795498
PMCPMC4369320

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.